[1] |
黄琼, 杨勤萍, 方栩, 等. 重组人Ⅱ型肿瘤坏死因子受体⁃抗体融合蛋白治疗寻常性银屑病多中心、随机、双盲试验[J]. 中华皮肤科杂志, 2007, 40(11): 655⁃658. DOI: 10.3760/j.issn:0412⁃4030.2007.11.001.
|
|
Huang Q, Yang QP, Fang X, et al. Treatment of psoriasis vulgaris with a recombinant human tumor necrosis factor receptor:Fc fusion protein:a multicentre, randomized, double blind trial[J]. Chin J Dermatol, 2007, 40(11): 655⁃658. DOI: 10.3760/j.issn:0412⁃4030.2007.11.001.
|
[2] |
李诚让, 杨雪源, 顾军, 等.重组人Ⅱ型肿瘤坏死因子受体⁃抗体融合蛋白治疗中重度寻常性银屑病的多中心临床研究[J].中华皮肤科杂志, 2015, 48(8): 547⁃550. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.08.007.
|
|
Li CR, Yang XY, Gu J, et al. Recombinant human tumor necrosis factor receptor type Ⅱ⁃IgG Fc fusion protein for the treatment of moderate to severe psoriasis vulgaris:a multi⁃centre, parallel⁃group, controlled clinical trial[J]. Chin J Dermatol, 2015, 48(8): 547⁃550. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.08.007.
|
[3] |
陈玲玲, 吴文雅, 施辛, 等. 重组人Ⅱ型肿瘤坏死因子受体⁃抗体融合蛋白治疗难治性红皮病性银屑病一例[J].中华皮肤科杂志, 2011, 44(12): 899⁃900. DOI: 10.3760/cma.j.issn.0412⁃4030.2011.12.030.
|
|
Chen LL, Wu WY, Shi X, et al. A case of refractory erythrodermic psoriasis treated with recombinant human tumor necrosis factor receptor type Ⅱ⁃IgG Fc fusion protein[J]. Chin J Dermatol, 2011, 44(12): 899⁃900. DOI: 10.3760/cma.j.issn.0412⁃4030.2011. 12.030.
|
[4] |
杨竹生, 林麟, 崔盘根, 等. 红皮病性银屑病193例分析[J]. 中华皮肤科杂志, 2007, 40(10): 634⁃636. DOI: 10.3760/j.issn:0412⁃4030.2007.10.015.
|
|
Yang ZS, Lin L, Cui PG, et al. A clinical analysis of 193 cases of erythrodermic psoriasis[J]. Chin J Dermatol, 2007, 40(10): 634⁃636. DOI: 10.3760/j.issn:0412⁃4030.2007.10.015.
|
[5] |
唐志铭, 翟晓翔, 荆梦晴. 308 nm准分子激光联合他扎罗汀凝胶治疗斑块状银屑病的疗效观察[J]. 中华皮肤科杂志, 2015, 48(4): 233⁃236. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.04.004.
|
|
Tang ZM, Zhai XX, Jing MQ. Efficacy of 308⁃nm excimer laser combined with tazarotene gel for the treatment of plaque psoriasis[J]. Chin J Dermatol, 2015, 48(4): 233⁃236.DOI: 10.3760/cma.j.issn.0412⁃4030.2015.04.004
|
[6] |
Krueger GG, Papp KA, Stough DB, et al. A randomized, double⁃blind, placebo⁃controlled phase Ⅲ study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis[J]. J Am Acad Dermatol, 2002, 47(6): 821⁃833. DOI: http://dx.doi.org/10.1067/mjd.2002.127247.
|
[7] |
中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗专家共识(2014版)[J]. 中华皮肤科杂志, 2014, 47(3): 213⁃215. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.03.017.
|
|
Psoriasis group of CSD. CMA. Consensus on the treatment of psoriasis in China (2014)[J]. Chin J Dermatol, 2014, 47(3): 213⁃215. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.03.017.
|
[8] |
Esposito M, Mazzotta A, de Felice C, et al. Treatment of erythro⁃dermic psoriasis with etanercept[J]. Br J Dermatol, 2006,155(1): 156⁃159. DOI: 10.1111/j.1365⁃2133.2006.07217.x.
|
[9] |
Papp KA, Tyring S, Lahfa M, et al. A global phase Ⅲ randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction[J]. Br J Dermatol, 2005, 152(6): 1304⁃1312. DOI: 10.1111/j.1365⁃2133.2005.06688.x.
|